
Home » BIOCRYST PHARMACEUTICALS ENTER AGREEMENT WITH GREEN CROSS TO DEVELOP AND COMMERICALIZE PERAMIVIR
BIOCRYST PHARMACEUTICALS ENTER AGREEMENT WITH GREEN CROSS TO DEVELOP AND COMMERICALIZE PERAMIVIR
BioCryst Pharmaceuticals (Nasdaq: BCRX) announced an agreement with Green Cross Corporation, South Korea for the development and commercialization in Korea of peramivir, BioCryst's potent influenza neuraminidase inhibitor.
StreetInsider.com (http://www.streetinsider.com/news.php?id=963334&st=p)
KEYWORDS Daily International Pharma Alert
Upcoming Events
-
13Jul
-
27Jul
-
28Jul
-
28Jul
-
02Aug
-
03Aug